Fluoxetine combined with clorazepate dipotassium and behaviour modification for treatment of anxiety-related disorders in dogs.
The effectiveness of clorazepate dipotassium combined with fluoxetine and a behaviour modification programme for the treatment of anxiety disorders in dogs was investigated. Forty dogs with anxiety disorders were initially enrolled and 36 dogs completed the trial. Dogs were classified into two behavioural categories (anxious dogs with aggression and anxious dogs without aggression) according to their presenting complaints, and were also subdivided into males, females, juveniles and adults. The dog owners were provided with a behaviour modification plan for their dogs to be commenced in the first week of therapy. Clorazepate dipotassium was administered PO at 1.0 mg/kg every 24 h for 4 weeks, and fluoxetine was administered PO at 1.0 mg/kg every 24 h for 10 weeks. Therapy with both drugs was initiated simultaneously. Improvement was reported in 25/36 dogs. Significant differences in treatment effects were observed between anxious dogs with aggression and anxious dogs without aggression (P<0.05). Positive correlations between owner compliance with the treatment plan and reported improvement achieved during three periods of study were also noted.
Universidad Complutense de Madrid, Facultad de Veterinaria, Clínica de Comportamiento Animal, Departamento de Producción Animal, Ciudad Universitaria, 28040 Madrid, Spain.
S
S
Pineda
Universidad Complutense de Madrid, Facultad de Veterinaria, Clínica de Comportamiento Animal, Departamento de Producción Animal, Ciudad Universitaria, 28040 Madrid, Spain.
B
B
Anzola
Universidad Complutense de Madrid, Facultad de Veterinaria, Clínica de Comportamiento Animal, Departamento de Producción Animal, Ciudad Universitaria, 28040 Madrid, Spain.
A
A
Olivares
Universidad Complutense de Madrid, Facultad de Veterinaria, Clínica de Comportamiento Animal, Departamento de Producción Animal, Ciudad Universitaria, 28040 Madrid, Spain. Electronic address: mibanez@vet.ucm.es.
M
M
Ibáñez
D000374:Aggression / Q000187:drug effects; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy / Q000628:therapy*; D001521:Behavior Therapy; D003009:Clorazepate Dipotassium / Q000494:pharmacology / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy / Q000628:therapy*; D004285:Dogs; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D013030:Spain
D014151:Anti-Anxiety Agents; D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D003009:Clorazepate Dipotassium
Aggression; Anxiety; Canine; Clorazepate; Fluoxetine